Shots:
Grünenthal & Bayer collaborated to acquire Nebido for ~$500M and the transaction is expected to close at the end of 2022. Grünenthal will acquire the global rights to Nebido
The divestment is part of an ongoing transformation of the pharmaceuticals business which focuses on healthcare innovation. Nebido is used for the treatment of male hypogonadism & is available to patients in ~80 countries globally & is patented until 2024 in the EU and 2027 in the US
The product is expected to add $100.38M to Grünenthal’s EBITDA in 2023. In the past few years, Grünenthal has invested ~$2.008B in profitable M&A transactions, leading to a markedly increased profitability
Ref: PRNewswire | Image: Bayer
